B. Braun Avitum AG and CytoSorbents Corporation Announce Global Co-Marketing Agreement to Promote the OMNI® Continuous Blood Purification Platform with CytoSorb®

$ 24.99

4.5 (536) In stock

Joint marketing of CytoSorb® with B. Braun’s newest OMNI® blood purification platform will offer greater access of this advanced treatment of deadly inflammation to critically ill patients.

In this image released on Tuesday, March 2, 2021, the CytoSorb® adsorber is used in critical care for the extracorporeal removal of cytokines and inflammatory mediators from the bloodstream. B. Braun Avitum

Digital Diabetes Management Market Size, Trends & Forecast

In this image released on Tuesday, March 2, 2021, the OMNI® extracorporeal platform is intended to perform continuous blood purification treatments and therapeutic plasma exchange. The OMNI® in combination with OMNIset®* disposable

Digital Diabetes Management Market Size, Trends & Forecast

B. Braun Avitum AG and CytoSorbents Corporation Announce Global Co-Marketing Agreement to Promote the OMNI® Continuous Blood Purification Platform with CytoSorb®

Apheresis Machines Market 2021: Comprehensive Study Explores

B. Braun Avitum AG and CytoSorbents Corporation Announce Global Co-Marketing Agreement to Promote the OMNI® Continuous Blood Purification Platform with CytoSorb® - Cytosorbents

Hip Replacement Devices Market Size, Share, Trends, Scope & Forecast

Hip Replacement Devices Market Size, Share, Trends, Scope & Forecast

B. Braun Avitum AG and CytoSorbents Corporation Announce Global Co-Marketing Agreement

新闻详情页-B. Braun Group

Apheresis Machines Market 2021: Comprehensive Study Explores